Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
Broman KK, Hughes TM, Dossett LA, Sun J, Carr MJ, Kirichenko DA, Sharma A, Bartlett EK, Nijhuis AA, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma J, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras RM, Teras J, Farrow NE, Beasley GM, Hui JY, Been L, Kruijff S, Boulware D, Sarnaik AA, Sondak VK, Zager JS; International High-Risk Melanoma Consortium. Broman KK, et al. Among authors: kirichenko da. J Am Coll Surg. 2021 Apr;232(4):424-431. doi: 10.1016/j.jamcollsurg.2020.11.014. Epub 2020 Dec 13. J Am Coll Surg. 2021. PMID: 33316427 Free PMC article.
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Broman KK, et al. Cancer. 2021 Jul 1;127(13):2251-2261. doi: 10.1002/cncr.33483. Epub 2021 Apr 7. Cancer. 2021. PMID: 33826754 Free PMC article.
Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.
Broman KK, Bettampadi D, Pérez-Morales J, Sun J, Kirichenko D, Carr MJ, Eroglu Z, Tarhini AA, Khushalani N, Schabath MB, Sarnaik A, Sondak VK, Zager JS. Broman KK, et al. Ann Surg Oncol. 2021 Nov;28(12):6978-6985. doi: 10.1245/s10434-021-10570-5. Epub 2021 Aug 6. Ann Surg Oncol. 2021. PMID: 34363118 Free PMC article.
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.
Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA; International High Risk Melanoma Consortium. Broman KK, et al. Ann Surg. 2023 May 1;277(5):e1106-e1115. doi: 10.1097/SLA.0000000000005370. Epub 2023 Apr 6. Ann Surg. 2023. PMID: 35129464 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34471988
Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.
Carr MJ, Sun J, Kroon HM, Miura JT, Beasley GM, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Kirichenko DA, Potdar A, Daou H, Mullen D, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Coventry BJ, Tyler DS, Thompson JF, Zager JS. Carr MJ, et al. Among authors: kirichenko da. Ann Surg Oncol. 2020 Dec;27(13):5107-5118. doi: 10.1245/s10434-020-09051-y. Epub 2020 Sep 11. Ann Surg Oncol. 2020. PMID: 32918177 Free PMC article.
The emergence of neoadjuvant therapy in advanced melanoma.
Sun J, Kirichenko DA, Zager JS, Eroglu Z. Sun J, et al. Among authors: kirichenko da. Melanoma Manag. 2019 Oct 18;6(3):MMT27. doi: 10.2217/mmt-2019-0007. Melanoma Manag. 2019. PMID: 31807278 Free PMC article. Review.
Monitoring of breast cancer progression via aptamer-based detection of circulating tumor cells in clinical blood samples.
Kolovskaya OS, Zyuzyukina AV, Dassie JP, Zamay GS, Zamay TN, Boyakova NV, Khorzhevskii VA, Kirichenko DA, Lapin IN, Shchugoreva IA, Artyushenko PV, Tomilin FN, Veprintsev DV, Glazyrin YE, Minic Z, Bozhenko VK, Kudinova EA, Kiseleva YY, Krat AV, Slepov EV, Bukatin AS, Zukov RA, Shesternya PA, Berezovski MV, Giangrande PH, Kichkailo AS. Kolovskaya OS, et al. Among authors: kirichenko da. Front Mol Biosci. 2023 Jun 8;10:1184285. doi: 10.3389/fmolb.2023.1184285. eCollection 2023. Front Mol Biosci. 2023. PMID: 37363395 Free PMC article.
12 results